http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0862556-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J73-00 |
| filingDate | 1996-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe752aa39d96d7725d5b274c2375f49d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ef9e11dcacbd4c69bb040cf12bff85a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a990da8dab7fa1cd9330a50f451d8774 |
| publicationDate | 2001-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0862556-B1 |
| titleOfInvention | 17-alkyl-7-substituted-4-aza steroid derivatives |
| abstract | The novel compounds of the present invention are those of structural formula (I), or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5 alpha -reductase, particularly 5 alpha -reductase type 1. The compounds of formula (I) are useful in the systemic, including oral, or parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia which includes female and male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as in the treatment of prostatitis. Methods of using the compounds of formula (I) for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis are provided, as well as pharmaceutical compositions for the compounds of formula (I). The use of compounds of formula (I) in combination with other active agents, for example with a 5 alpha -reductase type 2 inhibitor such as finasteride or epristeride, or a potassium channel opener, such as minoxidil, or a retinoic acid or a derivative thereof is also taught, wherein such combinations would be useful in one or more of the above-mentioned methods of treatment or pharmaceutical compositions. |
| priorityDate | 1995-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 431.